Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research and development (R&D) and commercialization cooperation agreement with ArriVent BioPharma, Inc. (NASDAQ: AVBP), a U.S. biopharmaceutical firm. The collaboration aims to jointly discover, develop, and commercialize innovative antibody-drug conjugates (ADCs) for oncology treatments.
According to the agreement, both companies will utilize Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify new ADC candidates for cancer therapies. The partnership grants ArriVent exclusive rights to develop and commercialize these ADCs globally, excluding Greater China (which includes mainland China, Hong Kong, Macau, and Taiwan), where Alphamab will maintain all rights.
The financial terms of the agreement encompass combined upfront and potential milestone payments that could total up to USD 615.5 million for Alphamab, contingent upon achieving specific regulatory, development, and sales milestones. Additionally, Alphamab is eligible to receive tiered sales royalties from ArriVent for each ADC product developed under the agreement.- Flcube.com
